Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Atogepant (Qulipta) is indicated for the preventive treatment of migraine in adults, showing efficacy in reducing monthly migraine days and other associated measures.
• Information about this drug's safety, tolerability, and efficacy in comparison to other drugs in the same class was gathered from six systematic reviews/meta-analyses.
• In comparison to monoclonal antibodies such as Erenumab, Eptinezumab, Fremanezumab, Galcanezumab, and other gepants like Rimegepant, Atogepant exhibited similar effectiveness. However, it was associated with higher odds of treatment-emergent adverse events when administered at a 120mg dose.
• Adverse events related to Atogepant are generally tolerable and do not significantly lead to discontinuation compared to placebo. Constipation and nausea were more commonly observed, especially at a higher dosage of 60mg/day.
• The studies reviewed included varied populations, including both episodic and chronic migraine sufferers, where all interventions proved more effective than placebo. This suggests Atogepant's utility across different migraine types, making it versatile within its clinical spectrum.
• The primary population studied was largely composed of adult females around the age group of 41 years, which is significant considering migraines disproportionately affect women.